Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Zhao JL, Antonarakis ES, Cheng HH, George DJ, Aggarwal R, Riedel E, Sumiyoshi T, Schonhoft JD, Anderson A, Mao N, Haywood S, Decker B, Curley T, Abida W, Feng FY, Knudsen K, Carver B, Lacouture ME, Wyatt AW, Rathkopf D. Zhao JL, et al. Among authors: schonhoft jd. Br J Cancer. 2024 Jan;130(1):53-62. doi: 10.1038/s41416-023-02487-5. Epub 2023 Nov 18. Br J Cancer. 2024. PMID: 37980367 Clinical Trial.
ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).
Fontana E, Rosen E, Lee EK, Højgaard M, Mettu NB, Lheureux S, Carneiro BA, Cote GM, Carter L, Plummer R, Mahalingam D, Fretland AJ, Schonhoft JD, Silverman IM, Wainszelbaum M, Xu Y, Ulanet D, Koehler M, Yap TA. Fontana E, et al. Among authors: schonhoft jd. J Natl Cancer Inst. 2024 May 6:djae098. doi: 10.1093/jnci/djae098. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 38710487
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Yap TA, Fontana E, Lee EK, Spigel DR, Højgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E. Yap TA, et al. Among authors: schonhoft jd. Nat Med. 2023 Jun;29(6):1400-1411. doi: 10.1038/s41591-023-02399-0. Epub 2023 Jun 5. Nat Med. 2023. PMID: 37277454 Free PMC article. Clinical Trial.
Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
Barnett ES, Schultz N, Stopsack KH, Lam ET, Arfe A, Lee J, Zhao JL, Schonhoft JD, Carbone EA, Keegan NM, Wibmer A, Wang Y, Solit DB, Abida W, Wenstrup R, Scher HI. Barnett ES, et al. Among authors: schonhoft jd. Eur Urol. 2023 Feb;83(2):112-120. doi: 10.1016/j.eururo.2022.08.010. Epub 2022 Sep 16. Eur Urol. 2023. PMID: 36123219 Free PMC article.
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Zhang B, et al. Among authors: schonhoft jd. Br J Cancer. 2022 Aug;127(3):569-576. doi: 10.1038/s41416-022-01811-9. Epub 2022 Apr 19. Br J Cancer. 2022. PMID: 35440668 Free PMC article.
Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.
Conteduca V, Ku SY, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, Slade M, Gilbertson C, Manohar J, Sigouros M, Wang Y, Dittamore R, Wenstrup R, Mosquera JM, Schonhoft JD, Beltran H. Conteduca V, et al. Among authors: schonhoft jd. NPJ Precis Oncol. 2021 Sep 13;5(1):84. doi: 10.1038/s41698-021-00227-7. NPJ Precis Oncol. 2021. PMID: 34518634 Free PMC article. No abstract available.
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.
Conteduca V, Ku SY, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, Slade M, Gilbertson C, Manohar J, Sigouros M, Wang Y, Dittamore R, Wenstrup R, Mosquera JM, Schonhoft JD, Beltran H. Conteduca V, et al. Among authors: schonhoft jd. NPJ Precis Oncol. 2021 Aug 12;5(1):76. doi: 10.1038/s41698-021-00211-1. NPJ Precis Oncol. 2021. PMID: 34385567 Free PMC article.
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
Scher HI, Armstrong AJ, Schonhoft JD, Gill A, Zhao JL, Barnett E, Carbone E, Lu J, Antonarakis ES, Luo J, Tagawa S, Dos Anjos CH, Yang Q, George D, Szmulewitz R, Danila DC, Wenstrup R, Gonen M, Halabi S. Scher HI, et al. Among authors: schonhoft jd. Eur J Cancer. 2021 Jun;150:83-94. doi: 10.1016/j.ejca.2021.02.042. Epub 2021 Apr 21. Eur J Cancer. 2021. PMID: 33894633 Free PMC article.
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
Brown LC, Halabi S, Schonhoft JD, Yang Q, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Barnett ES, Carbone EA, Zhao JL, Healy P, Anand M, Gill A, Jendrisak A, Berry WR, Gupta S, Gregory SG, Wenstrup R, Antonarakis ES, George DJ, Scher HI, Armstrong AJ. Brown LC, et al. Among authors: schonhoft jd. Clin Cancer Res. 2021 Jul 15;27(14):4077-4088. doi: 10.1158/1078-0432.CCR-20-3471. Epub 2021 Apr 5. Clin Cancer Res. 2021. PMID: 33820782 Free PMC article.
30 results